PDS Biotechnology Corporation (PDSB): Rasio rega marang prakiraan pendapatan
PDS Biotechnology is developing unique Versamune vaccines with the potential for monopoly pricing power. The forward price-to-sales valuation trend, based on GURU.Markets data, confirms this trajectory, while captures the current state of the parameter. Success is driven by transparent capital management and a strategy of forming strategic alliances with pharma behemoths for joint molecule trials.
Rincian analitis perusahaan pdsbiotech.com (PDSB)
- rega saham lan target rega konsensus:
- data kapitalisasi bursa:
- indikator nilai buku ekuitas:
- indikator total utang lan likuiditas perusahaan:
Rasio Total Utang marang Ekuitas PDS Biotechnology|PDSB - Rasio silihan jangka dawa marang modal|Utang jangka cendhak marang modal PDS Biotechnology Corporation|PDSB - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku PDS Biotechnology Corporation|PDSB - Utang jangka dawa|Utang jangka cendhak perusahaan PDS Biotechnology|Rasio cepet pdsbiotech.com
- data bathi bisnis lan rasio investasi:
PDSB - Bathi resik|Bathi sing dikarepake PDS Biotechnology|PDSB - Kapitalisasi marang bathi resik|Prakiraan rega marang bathi PDS Biotechnology Corporation|PDSB - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan PDS Biotechnology Corporation|PDSB - Bathi sadurunge ngurangi bunga, pajak, penyusutan, lan amortisasi|Bathi resik saben saham (EPS TTM) PDS Biotechnology|PDSB - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan pdsbiotech.com|PDSB - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep PDS Biotechnology
- rincian pendapatan lan dodolan:
Ringkesan analisis perusahaan:PDS Biotechnology Corp PDSB
Investors must determine whether the current valuation of PDS Biotechnology (PDSB) is justified or reflects a systemic business decline. Analyzing the company's forward P/S chart, which compares market capitalization against expected sales volume, reveals a potential "value trap" risk, which is critical for PDS Biotechnology (PDSB) given its dependence on clinical trial outcomes and the capital shortfall prior to vaccine commercialization.
Analisis pesaing
ImmunityBio - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Immunocore Holdings IMCR|JANX - Rasio rega marang prakiraan pendapatan|RCUS (Arcus Corp) - Kapitalisasi marang prakiraan pendapatan|Zymeworks Inc. (ZYME) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep tangotx.com (TNGX)|Multiplikator forward rega marang pendapatan IOVA|IMTX - Prakiraan rega marang pendapatan|Multiplikator forward rega marang pendapatan XNCR (Xencor Corp)|Rasio rega marang pendapatan sing dikarepake CMPX|Multiplikator Forward P/S REPL (Replimune Group, Inc.)|Rega forward marang dodolan LYEL|Innate Pharma - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Pyxis Oncology, Inc.|cgen.com (CGEN) - Rasio rega marang prakiraan pendapatan|IO Biotech Inc. - Rega forward marang dodolan|STRO (Sutro Biopharma, Inc.) - Multiplikator Forward P/S|Multiplikator Forward P/S minktherapeutics.com|Rasio rega marang prakiraan pendapatan Werewolf Therapeutics (HOWL)|IMMX: Rega mangsa ngarep marang pendapatan|ALX Oncology Holdings - Multiplikator forward rega marang pendapatan|cuebiopharma.com (CUE) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|SONN - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan MAIA|LIMN: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan LVTX|Rasio rega marang prakiraan pendapatan NextCure Corp|Leap Tx (LPTX) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan INTS (Intensity Therapeutics)|SNSE (senseibio.com) - Rega forward marang dodolan|Multiplikator Forward P/S TOVX (Theriva Biologics)|Gritstone bio Inc. - Rasio rega marang prakiraan pendapatan|Kineta Bio - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake NexImmune Corporation NEXI|turnstonebio.com (TSBX) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep vaccinex.com (VCNX)|Multiplikator forward rega marang pendapatan HARP
